Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$186.99
-0.4%		$202.04
$53.67
▼
$224.31
$40.08B1.42.84 million shs1.72 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-3.39%-0.83%-2.68%-0.81%+254.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$186.99
-0.4%		$202.04
$53.67
▼
$224.31
$40.08B1.42.84 million shs1.72 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-3.39%-0.83%-2.68%-0.81%+254.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.92
Moderate Buy$242.9029.90% Upside

Current Analyst Ratings Breakdown

Latest RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$250.00
10/19/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$240.00 ➝ $241.00
10/16/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageMarket Perform ➝ Outperform
10/15/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$275.00
10/14/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$259.00 ➝ $260.00
10/9/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$265.00 ➝ $264.00
10/8/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/8/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$251.00 ➝ $259.00
10/7/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$239.00 ➝ $240.00
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,461.09N/AN/A$8.44 per share22.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.35N/AN/AN/A$25.58 millionN/A
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883214.34 million198.05 millionOptionable

Recent News About These Companies

Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients
October 23 at 9:59 AM  |  msn.comhttps://www.msn.com/en-us/news/other/revolution-s-rasonque-improves-survival-across-subgroups-in-pancreatic-cancer-patients/ar-AA2fUFdM
RVMD's RASONQUE Shows Survival Benefit Across Key Patient Group In Metastatic Pancreatic Cancer
October 23 at 9:59 AM  |  rttnews.comhttps://www.rttnews.com/3702435/rvmd-s-rasonque-shows-survival-benefit-across-key-patient-group-in-metastatic-pancreatic-cancer.aspx
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
October 23 at 9:59 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-presents-overall-survival-113000436.html
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
October 23 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/23/3387179/0/en/revolution-medicines-presents-overall-survival-data-for-rasonque-daraxonrasib-across-subgroups-in-previously-treated-metastatic-pancreatic-cancer-at-esmo-2026.html
Revolution Medicines (NASDAQ:RVMD) Earns Buy Rating from TD Cowen
October 23 at 2:19 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148364
Revolution Medicines (NASDAQ:RVMD) Stock Price Up 5.5% on Analyst Upgrade
October 22 at 1:52 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31144830
Brookline Capital Markets Estimates RVMD Q3 Earnings
October 22 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31144592
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
October 21 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385895/0/en/revolution-medicines-to-report-financial-results-for-third-quarter-2026-after-market-close-on-november-4-2026.html
Revolution Medicines' (RVMD) Buy Rating Reiterated at TD Cowen
October 21 at 11:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-revolution-medicines-rvmd-buy-rating-reiterated-at-td-cowen-2026-10-21/
QP Wealth Management LLC Acquires 5,851 Shares of Revolution Medicines, Inc. $RVMD
October 21 at 7:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-qp-wealth-management-llc-acquires-5851-shares-of-revolution-medicines-inc-rvmd-2026-10-21/
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Truist Financial Analyst Says
October 21 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141030
Biotech Stocks Move Higher: MBRX Gains 15%, FEMY Rises 7%, RVMD Advances 7%, MYGN Surges Over 40%
October 20 at 4:06 PM  |  rttnews.comhttps://www.rttnews.com/3700724/biotech-stocks-move-higher-mbrx-gains-15-femy-rises-7-rvmd-advances-7-mygn-surges-over-40.aspx
Revolution Medicines (NASDAQ:RVMD) Shares Climb 5.5% on Analyst Upgrade
October 20 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-revolution-medicines-nasdaq-rvmd-shares-climb-55-on-analyst-upgrade-2026-10-20/
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
October 20 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384305/0/en/revolution-medicines-begins-treating-patients-in-phase-3-rasolve-308-trial-evaluating-zoldonrasib-in-combination-with-pembrolizumab-and-chemotherapy-as-first-line-treatment-for-pat.html
Research Analysts Issue Forecasts for RVMD Q3 Earnings
October 20 at 7:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-research-analysts-issue-forecasts-for-rvmd-q3-earnings-2026-10-20/
Truist Financial Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price
October 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-truist-financial-issues-positive-forecast-for-revolution-medicines-nasdaq-rvmd-stock-price-2026-10-19/
7,403 Shares in Revolution Medicines, Inc. $RVMD Purchased by SteelPeak Wealth LLC
October 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-7403-shares-in-revolution-medicines-inc-rvmd-purchased-by-steelpeak-wealth-llc-2026-10-19/
Revolution Medicines (NASDAQ:RVMD) Stock Rating Reaffirmed as Buy by Needham & Company LLC
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128198
RVMD Moves Key Pancreatic Cancer Combo Into Phase 3, Raising RAS Market Stakes
October 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rvmd-moves-key-pancreatic-cancer-combo-into-phase-3-raising-ras-market-stakes?utm_source=marketbeat.com&utm_medium=referral
Lilly, Pfizer, J&J among winners of EU drug recommendations this month
October 16, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/lilly-pfizer-j-j-among-winners-of-eu-drug-recommendations-this-month/ar-AA2endh0
Revolution Medicines, Inc. $RVMD Stock Acquired by Assenagon Asset Management S.A.
October 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-revolution-medicines-inc-rvmd-stock-acquired-by-assenagon-asset-management-sa-2026-10-16/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$186.99 -0.70 (-0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$185.93 -1.06 (-0.57%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas